Roxadustat + Placebo
Phase 3Terminated 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Primary MDS (Very Low, Low or Intermediate IPSS-R With <5% Blasts)
Conditions
Primary MDS (Very Low, Low or Intermediate IPSS-R With <5% Blasts), Anemia
Trial Timeline
Jan 29, 2018 → Jun 20, 2023
NCT ID
NCT03263091About Roxadustat + Placebo
Roxadustat + Placebo is a phase 3 stage product being developed by Astellas Pharma for Primary MDS (Very Low, Low or Intermediate IPSS-R With <5% Blasts). The current trial status is terminated. This product is registered under clinical trial identifier NCT03263091. Target conditions include Primary MDS (Very Low, Low or Intermediate IPSS-R With <5% Blasts), Anemia.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (4)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03263091 | Phase 3 | Terminated |
| NCT01887600 | Phase 3 | Completed |
| NCT01750190 | Phase 3 | Completed |
| NCT00761657 | Phase 2 | Completed |
Competing Products
20 competing products in Primary MDS (Very Low, Low or Intermediate IPSS-R With <5% Blasts)